MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF THEIR APPLICATION Russian patent published in 2023 - IPC C07D401/14 C07D401/04 C07D409/04 C07D409/14 C07D413/04 A61K31/4166 A61P11/00 A61P13/12 A61P19/02 

FIELD: pharmaceuticals.

SUBSTANCE: compounds based on hydantoin, useful as inhibitors of matrix metalloproteinases (MMPs), in particular macrophage elastase (MMP-12) are described. The invention relates to compounds based on hydantoin of formula (II) or its pharmaceutically acceptable salts, where ring B is pyridinyl or thiophenyl; ring C is phenyl; ring D is phenyl or pyridinyl; X is S; Y is O; Z is CH₂; R₁-R₅, m and n are defined in the claims. The compounds have activity as inhibitors of matrix metalloproteinases (MMPs), in particular macrophage elastase (MMP-12).

EFFECT: pharmaceutical compositions and methods of using the compounds for the inhibition of MMP-12 and the treatment of diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis are also described.

13 cl, 1 dwg, 3 tbl, 3 ex

(II)